Secondary use and scholarly impact of a portfolio of clinical trials with shared individual participant level data: cross sectional study
Erfan Taherifard, Maryam Mooghali, Hollin R.L. Hakimian, Sahil R. Mane et autres
1 citationBMJ
Johnson & Johnson (United Kingdom)
Edinburgh · GB · company
845Publications signalées
103058Citations signalées
12Thèmes principaux
Principaux domaines
Multiple Myeloma Research and TreatmentsHealth Systems, Economic Evaluations, Quality of LifeOcular Surface and Contact LensTotal Knee Arthroplasty OutcomesOrthopaedic implants and arthroplastyLung Cancer Treatments and MutationsProtein Degradation and InhibitorsInflammatory Bowel DiseaseOphthalmology and Visual Impairment StudiesCancer Treatment and PharmacologyBiosimilars and Bioanalytical MethodsAlzheimer's disease research and treatments
Évolution annuelle
Publications récentes
Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experience
Gang An, Jie Jin, Zhen Cai, Hongmei Jing et autres
0 citationsHematology
A Prospective, Multi-Center, Randomized Controlled Study to Evaluate the Efficacy and Safety of Two Absorbable Barbed Sutures in Thyroid Surgery
Xiuhe Zou, Ting Zhang, Wenxin Zhao, Yijun Wu et autres
0 citationsMedical Devices Evidence and Research
Process Development toward DHODH Inhibitor JNJ-6665
Kangying Li, Edward Cleator, Simon Wagschal, Shane Plunkett et autres
0 citationsACS Organic & Inorganic Au
siRNA daplusiran/tomligisiran and DNA vaccine JNJ-64300535 in NA-suppressed chronic hepatitis B: the OSPREY study
Stefan Bourgeois, Maria Buti, Edward J. Gane, Kosh Agarwal et autres
0 citationsnpj Vaccines
Daratumumab plus bortezomib, lenalidomide, and dexamethasone in transplant-deferred newly diagnosed multiple myeloma: Frailty subgroup analysis of CEPHEUS
Sonja Zweegman, Saad Z. Usmani, Vânia Hungria, Nizar J. Bahlis et autres
0 citationsLeukemia
MM-349: Teclistamab Plus Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma: Analysis of MajesTEC-3 Based on Cytogenetic and Functional Risk
Rahul Banerjee, Niels WCJ van de Donk, Roberto Mina, María-Victoria Mateos et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
POSTER: MM-338: Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma: Final Analysis of Transplant-Ineligible Patients in the Phase 3 CEPHEUS Study
Saad Z Usmani, Thierry Facon, Vania Hungria, Nizar J. Bahlis et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
POSTER: MM-349: Teclistamab Plus Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma: Analysis of MajesTEC-3 Based on Cytogenetic and Functional Risk
Rahul Banerjee, Niels WCJ van de Donk, Roberto Mina, María-Victoria Mateos et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
MM-326: New IMS/IMWG Consensus Genomic Staging Risk Criteria by Next-Generation Sequencing: Analysis of Daratumumab Benefit in Both High- and Standard-Risk Patients in the PERSEUS/EMN017 Study
Meletios Athanasios Dimopoulos, Carolina Terragna, Niccola Bolli, Philippe Moreau et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
MM-338: Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma: Final Analysis of Transplant-Ineligible Patients in the Phase 3 CEPHEUS Study
Saad Z Usmani, Thierry Facon, Vania Hungria, Nizar J. Bahlis et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
POSTER: MM-326: New IMS/IMWG Consensus Genomic Staging Risk Criteria by Next-Generation Sequencing: Analysis of Daratumumab Benefit in Both High- and Standard-Risk Patients in the PERSEUS/EMN017 Study
Meletios Athanasios Dimopoulos, Carolina Terragna, Niccola Bolli, Philippe Moreau et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.